Demographics, diagnosis, and gene mutations in patients with ABO antigen weakness and hematologic diseases
| . | Total (n = 103) . | A weak (n = 55) . | B weak (n = 32) . | Both (n = 16) . |
|---|---|---|---|---|
| Sex | ||||
| Male | 57 (55.3) | 30 (54.5) | 19 (59.4) | 8 (50.0) |
| Female | 46 (44.7) | 25 (45.5) | 13 (40.6) | 8 (50.0) |
| Age, mean, y | 51.4 | 51.8 | 51.1 | 50.9 |
| Hematologic diseases | ||||
| AML | 44 (42.7) | 23 (41.8) | 12 (37.5) | 9 (56.3) |
| ALL | 6 (5.8) | 5 (9.1) | 0 (0.0) | 1 (6.3) |
| MDS | 22 (21.4) | 12 (21.8) | 10 (31.3) | 0 (0.0) |
| AA | 8 (7.8) | 5 (9.1) | 1 (3.1) | 2 (12.5) |
| Genetic tested∗ | 64 | 35 | 19 | 10 |
| RUNX1 | 12 (18.8) | 8 (22.9) | 2 (10.5) | 2 (20.0) |
| GATA2 | 1 (1.6) | 0 (0.0) | 0 (0.0) | 1 (10.0) |
| CEBPA | 21 (32.8) | 12 (34.3) | 5 (26.3) | 4 (40.0) |
| NRAS | 11 (17.2) | 4 (11.4) | 4 (21.1) | 3 (30.0) |
| TET2 | 8 (12.5) | 3 (8.6) | 3 (15.8) | 2 (20.0) |
| U2AF1 | 8 (12.5) | 3 (8.6) | 5 (26.3) | 0 (0.0) |
| ASXL1 | 7 (10.9) | 6 (17.1) | 0 (0.0) | 1 (10.0) |
| FLT3 | 6 (9.4) | 4 (11.4) | 1 (5.3) | 1 (10.0) |
| PTPN11 | 6 (9.4) | 4 (11.4) | 1 (5.3) | 1 (10.0) |
| . | Total (n = 103) . | A weak (n = 55) . | B weak (n = 32) . | Both (n = 16) . |
|---|---|---|---|---|
| Sex | ||||
| Male | 57 (55.3) | 30 (54.5) | 19 (59.4) | 8 (50.0) |
| Female | 46 (44.7) | 25 (45.5) | 13 (40.6) | 8 (50.0) |
| Age, mean, y | 51.4 | 51.8 | 51.1 | 50.9 |
| Hematologic diseases | ||||
| AML | 44 (42.7) | 23 (41.8) | 12 (37.5) | 9 (56.3) |
| ALL | 6 (5.8) | 5 (9.1) | 0 (0.0) | 1 (6.3) |
| MDS | 22 (21.4) | 12 (21.8) | 10 (31.3) | 0 (0.0) |
| AA | 8 (7.8) | 5 (9.1) | 1 (3.1) | 2 (12.5) |
| Genetic tested∗ | 64 | 35 | 19 | 10 |
| RUNX1 | 12 (18.8) | 8 (22.9) | 2 (10.5) | 2 (20.0) |
| GATA2 | 1 (1.6) | 0 (0.0) | 0 (0.0) | 1 (10.0) |
| CEBPA | 21 (32.8) | 12 (34.3) | 5 (26.3) | 4 (40.0) |
| NRAS | 11 (17.2) | 4 (11.4) | 4 (21.1) | 3 (30.0) |
| TET2 | 8 (12.5) | 3 (8.6) | 3 (15.8) | 2 (20.0) |
| U2AF1 | 8 (12.5) | 3 (8.6) | 5 (26.3) | 0 (0.0) |
| ASXL1 | 7 (10.9) | 6 (17.1) | 0 (0.0) | 1 (10.0) |
| FLT3 | 6 (9.4) | 4 (11.4) | 1 (5.3) | 1 (10.0) |
| PTPN11 | 6 (9.4) | 4 (11.4) | 1 (5.3) | 1 (10.0) |
AA, aplastic anemia; ALL, acute lymphocytic leukemia.
Numbers and proportions of patients with each gene mutation among tested patients were described. Only tier 1, 2 variants of each gene were counted.